{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T06:43:38Z","timestamp":1771051418315,"version":"3.50.1"},"reference-count":188,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.biopha.2021.112282","type":"journal-article","created":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T07:53:15Z","timestamp":1633161195000},"page":"112282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative"],"prefix":"10.1016","volume":"144","author":[{"given":"Isaac","family":"Kyei-Barffour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel Akwetey","family":"Addo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enoch","family":"Aninagyei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Ghartey-Kwansah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Desmond Omane","family":"Acheampong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2021.112282_bib1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","article-title":"Origin and evolution of pathogenic coronaviruses","volume":"17","author":"Cui","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"issue":"4","key":"10.1016\/j.biopha.2021.112282_bib2","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.immuni.2020.03.007","article-title":"SARS-CoV-2 vaccines: status report","volume":"52","author":"Amanat","year":"2020","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.biopha.2021.112282_bib3","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1128\/MMBR.69.4.635-664.2005","article-title":"Navas-Martin m.b. reviews, Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus","volume":"69","author":"Weiss","year":"2005","journal-title":"Microbiol. Mol. Biol. Rev"},{"issue":"5","key":"10.1016\/j.biopha.2021.112282_bib4","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","article-title":"Imbalanced host response to SARS-CoV-2 drives development of COVID-19","volume":"181","author":"Blanco-Melo","year":"2020","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.biopha.2021.112282_bib5","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","article-title":"SARS and MERS: recent insights into emerging coronaviruses.","volume":"14","author":"E.","year":"2016","journal-title":"Nat Rev Microbiol"},{"issue":"7798","key":"10.1016\/j.biopha.2021.112282_bib6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"F.","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2021.112282_bib7","first-page":"110748","article-title":"Male predisposition to severe COVID-19: Review of evidence and potential therapeutic prospects","author":"D.O.","year":"2020","journal-title":"Biomeid Pharmacother"},{"issue":"6","key":"10.1016\/j.biopha.2021.112282_bib8","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jama.2020.27124","article-title":"Genetic variants of SARS-CoV-2\u2014what do they mean?","volume":"325","author":"A.S.","year":"2021","journal-title":"JAMA"},{"issue":"10223","key":"10.1016\/j.biopha.2021.112282_bib9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"N.","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2021.112282_bib10","first-page":"588E35","article-title":"Virological assessment of hospitalized patients with COVID-2019","volume":"(vol 581, pg 465, 2020),","author":"R.","year":"2020","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.biopha.2021.112282_bib11","first-page":"420","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Z.","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.biopha.2021.112282_bib12","first-page":"157","article-title":"WHO Declares COVID-19 a Pandemic","volume":"91","author":"Cucinotta","year":"2020","journal-title":"Acta Bio-Med.: Atenei Parm."},{"issue":"2","key":"10.1016\/j.biopha.2021.112282_bib13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41591-021-01230-y","article-title":"Looking beyond COVID-19 vaccine phase 3 trials","volume":"27","author":"J.H.","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.biopha.2021.112282_bib14","article-title":"The strategy of vaccination and global pandemic: how framing may thrive on strategy during and after Covid-19","volume":"24","author":"Z.","year":"2021","journal-title":"Eur Res Studies J"},{"key":"10.1016\/j.biopha.2021.112282_bib15","first-page":"1979","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2020"},{"issue":"10269","key":"10.1016\/j.biopha.2021.112282_bib16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"M.","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.biopha.2021.112282_bib17","first-page":"443","article-title":"Methodological Analysis: Randomized Controlled Trials for Pfizer and Moderna COVID-19 Vaccines","volume":"33","author":"D.","year":"2021","journal-title":"J Pediatr Health Care"},{"key":"10.1016\/j.biopha.2021.112282_bib18","article-title":"Roberts M.Jb O\u2019Doherty, Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study","volume":"373","author":"J.L.","year":"2021","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.biopha.2021.112282_bib19","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-CoV-2 and COVID-19","volume":"184","author":"A.","year":"2021","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.biopha.2021.112282_bib20","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.autrev.2016.07.030","article-title":"From HBV to HPV: designing vaccines for extensive and intensive vaccination campaigns worldwide","volume":"15","author":"D.","year":"2016","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.biopha.2021.112282_bib21","article-title":"Inter-pathogen peptide sharing and the original antigenic sin: solving a paradox","volume":"8","author":"D.","year":"2018","journal-title":"Open Immunol J"},{"issue":"5\u20136","key":"10.1016\/j.biopha.2021.112282_bib22","first-page":"285","article-title":"Human papillomavirus epitope mimicry and autoimmunity: the molecular truth of peptide sharing","volume":"86","author":"D.","year":"2019","journal-title":"Pathology"},{"key":"10.1016\/j.biopha.2021.112282_bib23","doi-asserted-by":"crossref","first-page":"108426","DOI":"10.1016\/j.clim.2020.108426","article-title":"On the molecular determinants of the SARS-CoV-2 attack","volume":"215","author":"D.","year":"2020","journal-title":"Clin Immunol"},{"issue":"5","key":"10.1016\/j.biopha.2021.112282_bib24","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s12026-020-09152-6","article-title":"Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine","volume":"68","author":"D.","year":"2020","journal-title":"Immunol Res"},{"key":"10.1016\/j.biopha.2021.112282_bib25","doi-asserted-by":"crossref","first-page":"107836","DOI":"10.1016\/j.jmgm.2021.107836","article-title":"Epitope mimicry analysis of SARS-COV-2 surface proteins and human lung proteins","volume":"105","author":"S.","year":"2021","journal-title":"J Mol Graph Model"},{"issue":"4","key":"10.1016\/j.biopha.2021.112282_bib26","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","article-title":"Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology","volume":"183","author":"Piccoli","year":"2020","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.biopha.2021.112282_bib27","article-title":"GREB1L as a candidate gene of Mayer\u2013Rokitansky\u2013K\u00fcster\u2013Hauser syndrome","volume":"64","author":"Barffour","year":"2021","journal-title":"Eur. J. Med. Genet."},{"issue":"6","key":"10.1016\/j.biopha.2021.112282_bib28","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41594-020-0440-6","article-title":"Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur","volume":"27","author":"Z.","year":"2020","journal-title":"Nat Struct Mol Biol"},{"issue":"10","key":"10.1016\/j.biopha.2021.112282_bib29","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41594-020-0479-4","article-title":"Controlling the SARS-CoV-2 spike glycoprotein conformation","volume":"27","author":"Henderson","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"2","key":"10.1016\/j.biopha.2021.112282_bib30","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.mehy.2007.04.043","article-title":"Acquired autoimmunity after viral vaccination is caused by molecular mimicry and antigen complimentarity in the presence of an immunologic adjuvant and specific HLA patterns","volume":"70","author":"Waisbren","year":"2008","journal-title":"Med Hypotheses"},{"issue":"3","key":"10.1016\/j.biopha.2021.112282_bib31","first-page":"217","article-title":"A study of molecular mimicry and immunological cross-reactivity between hepatitis B surface antigen and myelin mimics","volume":"12","author":"Bogdanos","year":"2005","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.biopha.2021.112282_bib32","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nm.4322","article-title":"A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models","volume":"23","author":"Shan","year":"2017","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.biopha.2021.112282_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1006\/viro.2002.1612","article-title":"Passive transfer of virus-specific antibodies confers protection against reproductive failure induced by a virulent strain of porcine reproductive and respiratory syndrome virus and establishes sterilizing immunity","volume":"302","author":"Osorio","year":"2002","journal-title":"Virology"},{"issue":"3","key":"10.1016\/j.biopha.2021.112282_bib34","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2174\/1568010054022024","article-title":"Macrophages in inflammation","volume":"4","author":"N.","year":"2005","journal-title":"Curr Drug Tragets Inflamm Allergy"},{"issue":"772","key":"10.1016\/j.biopha.2021.112282_bib35","article-title":"Innate Immune Cells\u2019 Contribution to Systemic Lupus Erythematosus","volume":"10","author":"A.A.","year":"2019","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.biopha.2021.112282_bib36","first-page":"a006049","article-title":"Signaling in innate immunity and inflammation","volume":"4","author":"K.","year":"2012","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1","key":"10.1016\/j.biopha.2021.112282_bib37","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev.immunol.20.083001.084359","article-title":"Innate immune recognition","volume":"20","author":"C.A.","year":"2002","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"10.1016\/j.biopha.2021.112282_bib38","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/08830185.2010.529976","article-title":"Pathogen recognition by the innate immune system","volume":"30","author":"H.","year":"2011","journal-title":"Int Rev Immunol"},{"issue":"5","key":"10.1016\/j.biopha.2021.112282_bib39","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors","volume":"11","author":"T.","year":"2010","journal-title":"Nat Immunol"},{"issue":"6","key":"10.1016\/j.biopha.2021.112282_bib40","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.cell.2010.01.022","article-title":"Pattern recognition receptors and inflammation","volume":"140","author":"O.","year":"2010","journal-title":"Cell"},{"issue":"7164","key":"10.1016\/j.biopha.2021.112282_bib41","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/nature06246","article-title":"Recognition of microorganisms and activation of the immune response","volume":"449","author":"R.","year":"2007","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.biopha.2021.112282_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003207","article-title":"Cooperativity between CD8+ T cells, non-neutralizing antibodies, and alveolar macrophages is important for heterosubtypic influenza virus immunity","volume":"9","author":"Laidlaw","year":"2013","journal-title":"PloS Pathog"},{"issue":"1","key":"10.1016\/j.biopha.2021.112282_bib43","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2215\/CJN.09430915","article-title":"B cells, antibodies, and more","volume":"11","author":"Hoffman","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.biopha.2021.112282_bib44","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1146\/annurev-immunol-042718-041356","article-title":"Double-stranded RNA sensors and modulators in innate immunity","volume":"37","author":"Hur","year":"2019","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"10.1016\/j.biopha.2021.112282_bib45","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.immuni.2019.03.025","article-title":"Shared and distinct functions of type I and type III interferons","volume":"50","author":"Lazear","year":"2019","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.biopha.2021.112282_bib46","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nri722","article-title":"Chemokine receptors: multifaceted therapeutic targets","volume":"2","author":"Proudfoot","year":"2002","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"10.1016\/j.biopha.2021.112282_bib47","doi-asserted-by":"crossref","first-page":"a016303","DOI":"10.1101\/cshperspect.a016303","article-title":"The chemokine system in innate immunity","volume":"7","author":"Sokol","year":"2015","journal-title":"Cold Sprong Harb Perspect Biol"},{"issue":"4","key":"10.1016\/j.biopha.2021.112282_bib48","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/nri2729","article-title":"Effector and regulatory B cells: modulators of CD4+ T cell immunity","volume":"10","author":"Lund","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"6508","key":"10.1016\/j.biopha.2021.112282_bib49","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1126\/science.abc6261","article-title":"Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans","volume":"369","author":"Arunachalam","year":"2020","journal-title":"Science"},{"issue":"6515","key":"10.1016\/j.biopha.2021.112282_bib50","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.biopha.2021.112282_bib51","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1038\/s41591-020-1038-6","article-title":"A dynamic COVID-19 immune signature includes associations with poor prognosis","volume":"26","author":"Laing","year":"2020","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.biopha.2021.112282_bib52","doi-asserted-by":"crossref","first-page":"362","DOI":"10.7326\/M20-3012","article-title":"Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review","volume":"173","author":"Oran","year":"2020","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.biopha.2021.112282_bib53","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41591-020-0901-9","article-title":"Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19","volume":"26","author":"Liao","year":"2020","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.biopha.2021.112282_bib54","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","article-title":"Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity","volume":"183","author":"Moderbacher","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.biopha.2021.112282_bib55","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","article-title":"Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19","volume":"183","author":"Sekine","year":"2020","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.biopha.2021.112282_bib56","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.cell.2020.10.005","article-title":"Vascular disease and thrombosis in SARS-CoV-2-infected rhesus macaques","volume":"183","author":"Aid","year":"2020","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.biopha.2021.112282_bib57","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.138070","article-title":"Clinical and pathological investigation of patients with severe COVID-19","volume":"5","author":"Li","year":"2020","journal-title":"JCI Insight"},{"issue":"7821","key":"10.1016\/j.biopha.2021.112282_bib58","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-020-2588-y","article-title":"Longitudinal analyses reveal immunological misfiring in severe COVID-19","volume":"584","author":"Lucas","year":"2020","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.biopha.2021.112282_bib59","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201012","article-title":"Neutrophil extracellular traps infiltrate the lung airway, interstitial, and vascular compartments in severe COVID-19","volume":"217","author":"Radermecker","year":"2020","journal-title":"J Exp Med"},{"issue":"7","key":"10.1016\/j.biopha.2021.112282_bib60","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1016\/S2666-5247(20)30144-0","article-title":"Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study","volume":"1","author":"Schurink","year":"2020","journal-title":"Lancet Microb"},{"key":"10.1016\/j.biopha.2021.112282_bib61","article-title":"Impact of SARS-CoV-2 viral load on risk of intubation and mortality among hospitalized patients with coronavirus disease","author":"Magleby","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"49","key":"10.1016\/j.biopha.2021.112282_bib62","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abd7114","article-title":"Comprehensive mapping of immune perturbations associated with severe COVID-19","volume":"5","author":"Kuri-Cervantes","year":"2020","journal-title":"Sci Immunol"},{"issue":"7","key":"10.1016\/j.biopha.2021.112282_bib63","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"issue":"7830","key":"10.1016\/j.biopha.2021.112282_bib64","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.biopha.2021.112282_bib65","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41590-020-0782-6","article-title":"Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19","volume":"21","author":"Peng","year":"2020","journal-title":"Nat Immunol"},{"issue":"3","key":"10.1016\/j.biopha.2021.112282_bib66","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1128\/JVI.01281-09","article-title":"Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB\/c mice: CD4+ T cells are important in control of SARS-CoV infection","volume":"84","author":"Chen","year":"2010","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.biopha.2021.112282_bib67","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.immuni.2016.05.006","article-title":"Airway memory CD4+ T cells mediate protective immunity against emerging respiratory coronaviruses","volume":"44","author":"Zhao","year":"2016","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.biopha.2021.112282_bib68","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nri3803","article-title":"A brief history of T cell help to B cells","volume":"15","author":"Crotty","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"14","key":"10.1016\/j.biopha.2021.112282_bib69","doi-asserted-by":"crossref","first-page":"e00141","DOI":"10.1128\/JVI.00141-18","article-title":"Intrastructural help: harnessing T helper cells induced by licensed vaccines for improvement of HIV Env antibody responses to virus-like particle vaccines","volume":"92","author":"Elsayed","year":"2018","journal-title":"J Virol"},{"issue":"6512","key":"10.1016\/j.biopha.2021.112282_bib70","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1126\/science.abd3871","article-title":"Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans","volume":"370","author":"Mateus","year":"2020","journal-title":"Science"},{"issue":"7821","key":"10.1016\/j.biopha.2021.112282_bib71","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","article-title":"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls","volume":"584","author":"Le Bert","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biopha.2021.112282_bib72","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41590-020-00808-x","article-title":"SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition","volume":"22","author":"Nelde","year":"2021","journal-title":"Nat Immunol"},{"issue":"12","key":"10.1016\/j.biopha.2021.112282_bib73","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/eji.202048908","article-title":"Divergent SARS\u2010CoV\u20102\u2013specific T\u2010and B\u2010cell responses in severe but not mild COVID\u201019 patients","volume":"50","author":"Oja","year":"2020","journal-title":"Eur J Immunol"},{"issue":"6","key":"10.1016\/j.biopha.2021.112282_bib74","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0092-8674(00)80702-3","article-title":"A novel transcription factor, T-bet, directs Th1 lineage commitment","volume":"100","author":"Szabo","year":"2000","journal-title":"Cell"},{"issue":"32","key":"10.1016\/j.biopha.2021.112282_bib75","doi-asserted-by":"crossref","first-page":"14292","DOI":"10.1073\/pnas.1009234107","article-title":"Proinflammatory T helper type 17 cells are effective B-cell helpers","volume":"107","author":"Mitsdoerffer","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.biopha.2021.112282_bib76","series-title":"Definition of B cell helper T cells in rheumatoid arthritis and their behavior during treatment, Seminars in Arthritis and Rheumatism","author":"Lucas","year":"2020"},{"issue":"7833","key":"10.1016\/j.biopha.2021.112282_bib77","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2598-9","article-title":"Fauchere, SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19","volume":"587","author":"Braun","year":"2020","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.biopha.2021.112282_bib78","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.immuni.2019.04.011","article-title":"T follicular helper cell biology: a decade of discovery and diseases","volume":"50","author":"Crotty","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.biopha.2021.112282_bib79","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3389\/fimmu.2021.666388","article-title":"Role of Circulating T Follicular Helper Cells and Stem-Like Memory CD4+ T Cells in the Pathogenesis of HIV-2 Infection and Disease Progression","volume":"12","author":"Ponnan","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.biopha.2021.112282_bib80","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1086\/589862","article-title":"Vaccines: correlates of vaccine-induced immunity","volume":"47","author":"Plotkin","year":"2008","journal-title":"Clin infect Dis"},{"key":"10.1016\/j.biopha.2021.112282_bib81","doi-asserted-by":"crossref","first-page":"108309","DOI":"10.1016\/j.clim.2019.108309","article-title":"NFKB2 regulates human Tfh and Tfr pool formation and germinal center potential","volume":"210","author":"De Leo","year":"2020","journal-title":"Clin Immunol"},{"key":"10.1016\/j.biopha.2021.112282_bib82","article-title":"Multiscale Modeling of Germinal Center Recapitulates the Temporal Transition From Memory B Cells to Plasma Cells Differentiation as Regulated by Antigen Affinity-Based Tfh Cell Help","volume":"11","author":"Tejero","year":"2020","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.biopha.2021.112282_bib83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203037","article-title":"Induction of circulating T follicular helper cells and regulatory T cells correlating with HIV-1 gp120 variable loop antibodies by a subtype C prophylactic vaccine tested in a Phase I trial in India","volume":"13","author":"Munusamy Ponnan","year":"2018","journal-title":"PloS One"},{"issue":"55","key":"10.1016\/j.biopha.2021.112282_bib84","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abb6852","article-title":"Tissue-resident CD4+ T helper cells assist the development of protective respiratory B and CD8+ T cell memory responses","volume":"6","author":"Son","year":"2021","journal-title":"Sci Immunol"},{"issue":"1","key":"10.1016\/j.biopha.2021.112282_bib85","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1146\/annurev.immunol.20.100101.151926","article-title":"T cell memory","volume":"20","author":"Sprent","year":"2002","journal-title":"Annu Rev Immunol"},{"issue":"5258","key":"10.1016\/j.biopha.2021.112282_bib86","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1126\/science.272.5258.54","article-title":"Immunological memory and protective immunity: understanding their relation","volume":"272","author":"Ahmed","year":"1996","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.biopha.2021.112282_bib87","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41591-020-01143-2","article-title":"Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells","volume":"27","author":"Schulien","year":"2021","journal-title":"Nat Med"},{"issue":"6504","key":"10.1016\/j.biopha.2021.112282_bib88","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.abc5902","article-title":"Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability","volume":"369","author":"Brouwer","year":"2020","journal-title":"Science"},{"issue":"7821","key":"10.1016\/j.biopha.2021.112282_bib89","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","article-title":"Convergent antibody responses to SARS-CoV-2 in convalescent individuals","volume":"584","author":"Robbiani","year":"2020","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.biopha.2021.112282_bib90","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1056\/NEJMoa2026116","article-title":"Humoral immune response to SARS-CoV-2 in Iceland","volume":"383","author":"Gudbjartsson","year":"2020","journal-title":"N Eng J Med"},{"issue":"6521","key":"10.1016\/j.biopha.2021.112282_bib91","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1126\/science.abd7728","article-title":"Robust neutralizing antibodies to SARS-CoV-2 infection persist for months","volume":"370","author":"Wajnberg","year":"2020","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.biopha.2021.112282_bib92","doi-asserted-by":"crossref","first-page":"100040","DOI":"10.1016\/j.xcrm.2020.100040","article-title":"Rapid generation of neutralizing antibody responses in COVID-19 patients","volume":"1","author":"Suthar","year":"2020","journal-title":"Cell Rep. Med."},{"issue":"52","key":"10.1016\/j.biopha.2021.112282_bib93","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abe5511","article-title":"Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients","volume":"5","author":"Isho","year":"2020","journal-title":"Sci Immunol"},{"issue":"48","key":"10.1016\/j.biopha.2021.112282_bib94","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abc8413","article-title":"The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients","volume":"5","author":"Premkumar","year":"2020","journal-title":"Sci. Immunol"},{"issue":"6506","key":"10.1016\/j.biopha.2021.112282_bib95","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1126\/science.abc7520","article-title":"Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model","volume":"369","author":"Rogers","year":"2020","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.biopha.2021.112282_bib96","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/j.cell.2021.02.010","article-title":"Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection","volume":"184","author":"Anderson","year":"2021","journal-title":"Cell"},{"issue":"6522","key":"10.1016\/j.biopha.2021.112282_bib97","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.abe1107","article-title":"Preexisting and de novo humoral immunity to SARS-CoV-2 in humans","volume":"370","author":"Ng","year":"2020","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.biopha.2021.112282_bib98","doi-asserted-by":"crossref","first-page":"e01991","DOI":"10.1128\/mBio.01991-20","article-title":"S protein-reactive IgG and memory B cell production after human SARS-CoV-2 infection includes broad reactivity to the S2 subunit","volume":"11","author":"Nguyen-Contant","year":"2020","journal-title":"MBio"},{"issue":"6520","key":"10.1016\/j.biopha.2021.112282_bib99","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd4250","article-title":"Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity","volume":"370","author":"Shrock","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.biopha.2021.112282_bib100","first-page":"1","article-title":"Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection","volume":"12","author":"Song","year":"2021","journal-title":"Nat. Commun."},{"issue":"6529","key":"10.1016\/j.biopha.2021.112282_bib101","doi-asserted-by":"crossref","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.biopha.2021.112282_bib102","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0952-7915(00)00211-9","article-title":"Generation and maintenance of memory T cells","volume":"13","author":"Sprent","year":"2001","journal-title":"Curr Opin Immunol"},{"issue":"6640","key":"10.1016\/j.biopha.2021.112282_bib103","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/41131","article-title":"A human homologue of the Drosophila Toll protein signals activation of adaptive immunity","volume":"388","author":"Medzhitov","year":"1997","journal-title":"Nature"},{"issue":"5343","key":"10.1016\/j.biopha.2021.112282_bib104","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1126\/science.278.5343.1612","article-title":"IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling","volume":"278","author":"Muzio","year":"1997","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.biopha.2021.112282_bib105","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1146\/annurev.immunol.18.1.593","article-title":"The role of chemokine receptors in primary, effector, and memory immune responses","volume":"18","author":"Sallusto","year":"2000","journal-title":"Ann Rev Immunol"},{"issue":"7","key":"10.1016\/j.biopha.2021.112282_bib106","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/89726","article-title":"Dendritic cell lineage, plasticity and cross-regulation","volume":"2","author":"Liu","year":"2001","journal-title":"Nat Immunol"},{"issue":"4","key":"10.1016\/j.biopha.2021.112282_bib107","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.4049\/jimmunol.163.4.1817","article-title":"Strong TCR ligation without costimulation causes rapid onset of Fas-dependent apoptosis of naive murine CD4+ T cells","volume":"163","author":"Kishimoto","year":"1999","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.biopha.2021.112282_bib108","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41577-021-00526-x","article-title":"COVID-19 vaccines: modes of immune activation and future challenges","volume":"21","author":"Teijaro","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.biopha.2021.112282_bib109","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/sj.gt.3301117","article-title":"The promise of nucleic acid vaccines","volume":"7","author":"Restifo","year":"2000","journal-title":"Gene Ther"},{"key":"10.1016\/j.biopha.2021.112282_bib110","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/794528","article-title":"RNA-based vaccines in cancer immunotherapy","volume":"2015","author":"McNamara","year":"2015","journal-title":"J Immunol Res"},{"issue":"4","key":"10.1016\/j.biopha.2021.112282_bib111","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology, Nature reviews","volume":"17","author":"Pardi","year":"2018","journal-title":"Drug Discov."},{"key":"10.1016\/j.biopha.2021.112282_bib112","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41541-017-0032-6","article-title":"Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines","volume":"2","author":"Lutz","year":"2017","journal-title":"NPJ Vaccin."},{"key":"10.1016\/j.biopha.2021.112282_bib113","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3389\/fimmu.2019.00594","article-title":"Advances in mRNA vaccines for infectious diseases","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.biopha.2021.112282_bib114","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol Ther"},{"issue":"5","key":"10.1016\/j.biopha.2021.112282_bib115","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.tibs.2020.11.010","article-title":"Nucleic Acid-Based Technologies Targeting Coronaviruses","volume":"46","author":"Le","year":"2021","journal-title":"Trends Biochem. Sci."},{"issue":"7830","key":"10.1016\/j.biopha.2021.112282_bib116","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.biopha.2021.112282_bib117","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"J.H. Beigel, An mRNA Vaccine against SARS-CoV-2 - Preliminary Report","volume":"383","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"7830","key":"10.1016\/j.biopha.2021.112282_bib118","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2021.112282_bib119","article-title":"Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine","author":"Sahin","year":"2020","journal-title":"MedRxiv"},{"key":"10.1016\/j.biopha.2021.112282_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.tips.2020.08.004","article-title":"Paving the road for RNA therapeutics","author":"Dammes","year":"2020","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"10.1016\/j.biopha.2021.112282_bib121","first-page":"98","article-title":"t. science, Targeting RNA: a transformative therapeutic strategy","volume":"12","author":"Yin","year":"2019","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.biopha.2021.112282_bib122","first-page":"7052","article-title":"Rational design of antisense oligonucleotides modulating the activity of TLR7\/8 agonists","volume":"48","author":"Alharbi","year":"2020","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"10.1016\/j.biopha.2021.112282_bib123","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","volume":"19","author":"Roberts","year":"2020","journal-title":"Advances in oligonucleotide drug delivery., Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.biopha.2021.112282_bib124","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2014 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.biopha.2021.112282_bib125","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41577-020-00434-6","article-title":"Immunological considerations for COVID-19 vaccine strategies","volume":"20","author":"Jeyanathan","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2021.112282_bib126","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.coi.2021.03.008","article-title":"Ebola virus disease: current vaccine solutions","volume":"71","author":"Tomori","year":"2021","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"10.1016\/j.biopha.2021.112282_bib127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/imm.12829","article-title":"Novel viral vectors in infectious diseases","volume":"153","author":"Humphreys","year":"2018","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.biopha.2021.112282_bib128","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nrmicro2240","article-title":"Viruses as vaccine vectors for infectious diseases and cancer","volume":"8","author":"Draper","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.biopha.2021.112282_bib129","doi-asserted-by":"crossref","first-page":"16030","DOI":"10.1038\/mtm.2016.30","article-title":"Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens","volume":"3","author":"Afkhami","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.biopha.2021.112282_bib130","article-title":"Top US scientists left out of White House selection of COVID-19 vaccine short list","author":"Cohen","year":"2020","journal-title":"Science"},{"issue":"115","key":"10.1016\/j.biopha.2021.112282_bib131","doi-asserted-by":"crossref","first-page":"115ra2","DOI":"10.1126\/scitranslmed.3002925","article-title":"Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species","volume":"4","author":"Colloca","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"12","key":"10.1016\/j.biopha.2021.112282_bib132","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1080\/21645515.2017.1383575","article-title":"Chimpanzee adenoviral vectors as vaccines for outbreak pathogens","volume":"13","author":"Ewer","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"issue":"7","key":"10.1016\/j.biopha.2021.112282_bib133","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1473-3099(20)30160-2","article-title":"Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial","volume":"20","author":"Folegatti","year":"2020","journal-title":"Lancet Infect. Dis."},{"issue":"4","key":"10.1016\/j.biopha.2021.112282_bib134","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.vaccine.2019.10.102","article-title":"A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults","volume":"38","author":"Wilkie","year":"2020","journal-title":"Vaccine"},{"issue":"10249","key":"10.1016\/j.biopha.2021.112282_bib135","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet (Lond., Engl.)"},{"issue":"1","key":"10.1016\/j.biopha.2021.112282_bib136","doi-asserted-by":"crossref","DOI":"10.47611\/jsr.v10i1.1159","article-title":"A Review of the Animal and Human Trials of the Ad5-nCoV Vaccine Candidate","volume":"10","author":"Xi","year":"2021","journal-title":"J Stud Res"},{"issue":"205","key":"10.1016\/j.biopha.2021.112282_bib137","doi-asserted-by":"crossref","first-page":"205ra134","DOI":"10.1126\/scitranslmed.3006843","article-title":"A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity","volume":"5","author":"Smaill","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"7","key":"10.1016\/j.biopha.2021.112282_bib138","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1473-3099(11)70098-6","article-title":"Safety and efficacy of the HVTN 503\/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study","volume":"11","author":"Gray","year":"2011","journal-title":"Lancet Infect. Dis."},{"issue":"2","key":"10.1016\/j.biopha.2021.112282_bib139","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.vaccine.2010.10.037","article-title":"A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults","volume":"29","author":"Ledgerwood","year":"2010","journal-title":"Vaccine"},{"issue":"10249","key":"10.1016\/j.biopha.2021.112282_bib140","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"issue":"10240","key":"10.1016\/j.biopha.2021.112282_bib141","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.biopha.2021.112282_bib142","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nm1590","volume":"13","author":"Baccala","year":"2007","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.biopha.2021.112282_bib143","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/0264-410X(95)00211-I","article-title":"Inactivated poliovirus vaccine: past and present experience","volume":"14","author":"Murdin","year":"1996","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.biopha.2021.112282_bib144","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1016\/j.vaccine.2009.01.125","article-title":"Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring","volume":"27","author":"Vellozzi","year":"2009","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.biopha.2021.112282_bib145","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/nrmicro979","article-title":"From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza","volume":"2","author":"Wood","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"issue":"1","key":"10.1016\/j.biopha.2021.112282_bib146","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s12967-019-2116-8","article-title":"Epitope-based peptide vaccine design and target site depiction against Middle East Respiratory Syndrome Coronavirus: an immune-informatics study","volume":"17","author":"Tahir Ul Qamar","year":"2019","journal-title":"J. Transl. Med."},{"issue":"6501","key":"10.1016\/j.biopha.2021.112282_bib147","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1126\/science.abb9983","article-title":"Site-specific glycan analysis of the SARS-CoV-2 spike","volume":"369","author":"Watanabe","year":"2020","journal-title":"Science (N. Y. N. Y.)"},{"issue":"3","key":"10.1016\/j.biopha.2021.112282_bib148","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","article-title":"Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.biopha.2021.112282_bib149","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S1473-3099(21)00020-7","article-title":"Inactivated COVID-19 vaccines to make a global impact","volume":"21","author":"Iversen","year":"2021","journal-title":"Lancet Infect. Dis."},{"issue":"23","key":"10.1016\/j.biopha.2021.112282_bib150","doi-asserted-by":"crossref","first-page":"12201","DOI":"10.1128\/JVI.06048-11","article-title":"A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge","volume":"85","author":"Bolles","year":"2011","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.biopha.2021.112282_bib151","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.chom.2020.04.021","article-title":"The Challenges of Vaccine Development against a New Virus during a Pandemic","volume":"27","author":"Diamond","year":"2020","journal-title":"Cell host Microbe"},{"key":"10.1016\/j.biopha.2021.112282_bib152","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.smim.2018.05.001","article-title":"Correlates of adjuvanticity: A review on adjuvants in licensed vaccines","volume":"39","author":"Del Giudice","year":"2018","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.biopha.2021.112282_bib153","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41541-018-0089-x","article-title":"Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want","volume":"3","author":"HogenEsch","year":"2018","journal-title":"NPJ Vaccin."},{"issue":"6499","key":"10.1016\/j.biopha.2021.112282_bib154","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.abc1932","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","volume":"369","author":"Gao","year":"2020","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.biopha.2021.112282_bib155","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1080\/21645515.2016.1181236","article-title":"Mucosal adjuvants: Opportunities and challenges","volume":"12","author":"Zeng","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"issue":"14","key":"10.1016\/j.biopha.2021.112282_bib156","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1056\/NEJMp048180","article-title":"The Cutter incident, 50 years later","volume":"352","author":"Offit","year":"2005","journal-title":"N Eng J Med"},{"issue":"1","key":"10.1016\/j.biopha.2021.112282_bib157","first-page":"29","article-title":"The Cutter Incident. Poliomyelitis following Formaldehyde-Inactivated Poliovirus Vaccination in the United States during the Spring of 1955. II","volume":"78","author":"Nathanson","year":"1963","journal-title":"Relatsh. Polio. Cut. Vaccin."},{"key":"10.1016\/j.biopha.2021.112282_bib158","doi-asserted-by":"crossref","unstructured":"A.Z. Kapikian, R.H. Mitchell, R.M. Chanock, R.A. Shvedoff, C.E.J.A.j.o.e. Stewart, An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine, 89(4) (1969) 405\u2013421.","DOI":"10.1093\/oxfordjournals.aje.a120954"},{"issue":"4","key":"10.1016\/j.biopha.2021.112282_bib159","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine","volume":"89","author":"Kim","year":"1969","journal-title":"Am J Epidemiol"},{"issue":"1\u20133","key":"10.1016\/j.biopha.2021.112282_bib160","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s12026-007-0071-6","article-title":"Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease","volume":"39","author":"Castilow","year":"2007","journal-title":"Immunol Res"},{"issue":"1","key":"10.1016\/j.biopha.2021.112282_bib161","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nm.1894","article-title":"Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease","volume":"15","author":"Delgado","year":"2009","journal-title":"Nat. Med"},{"issue":"1","key":"10.1016\/j.biopha.2021.112282_bib162","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1097\/01.inf.0000108192.94692.d2","article-title":"Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection","volume":"23","author":"Johnson","year":"2004","journal-title":"Pediatr Infct Dis"},{"key":"10.1016\/j.biopha.2021.112282_bib163","first-page":"191","article-title":"Measles: old vaccines, new vaccines","author":"Griffin","year":"2009","journal-title":"Curr Top Micribiol Immunol"},{"issue":"2","key":"10.1016\/j.biopha.2021.112282_bib164","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1128\/jcm.11.2.120-122.1980","article-title":"Rabies virus inactivation by binary ethylenimine: new method for inactivated vaccine production","volume":"11","author":"Larghi","year":"1980","journal-title":"J Clin Microbiol"},{"issue":"1","key":"10.1016\/j.biopha.2021.112282_bib165","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijid.2003.09.002","article-title":"In vitro inactivation of the rabies virus by ascorbic acid","volume":"8","author":"Madhusudana","year":"2004","journal-title":"Int J Infect Dis"},{"issue":"6","key":"10.1016\/j.biopha.2021.112282_bib166","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/nm.2763","article-title":"Development of a new hydrogen peroxide\u2013based vaccine platform","volume":"18","author":"Amanna","year":"2012","journal-title":"Nat. Med."},{"issue":"15","key":"10.1016\/j.biopha.2021.112282_bib167","first-page":"2691","article-title":"Immunogenicity and protective efficacy of a psoralen-inactivated dengue-1 virus vaccine candidate in Aotus nancymaae monkeys","volume":"29","author":"Maves","year":"2011","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.biopha.2021.112282_bib168","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.vaccine.2009.10.126","article-title":"Comparison of the immunological responses and efficacy of gamma-irradiated V3526 vaccine formulations against subcutaneous and aerosol challenge with Venezuelan equine encephalitis virus subtype IAB","volume":"28","author":"Martin","year":"2010","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.biopha.2021.112282_bib169","first-page":"63","volume":"41","author":"Nims","year":"2013","journal-title":"Polyomavirus inactivation\u2013a review"},{"issue":"9","key":"10.1016\/j.biopha.2021.112282_bib170","first-page":"1965","article-title":"DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors","volume":"58","author":"Chen","year":"1998","journal-title":"acncer Res"},{"issue":"15","key":"10.1016\/j.biopha.2021.112282_bib171","first-page":"4155","article-title":"Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice","volume":"54","author":"Minev","year":"1994","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.biopha.2021.112282_bib172","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1074-7613(95)80001-8","article-title":"Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines","volume":"2","author":"Xiang","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.biopha.2021.112282_bib173","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taab104","article-title":"Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152\/Covaxin","author":"Yadav","year":"2021","journal-title":"J. Travel Med."},{"issue":"12","key":"10.1016\/j.biopha.2021.112282_bib174","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1080\/21645515.2020.1820808","article-title":"Recombinant vaccines for COVID-19","volume":"16","author":"Yadav","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"issue":"5","key":"10.1016\/j.biopha.2021.112282_bib175","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1473-3099(20)30988-9","article-title":"Optimism and caution for an inactivated COVID-19 vaccine","volume":"21","author":"Rostad","year":"2021","journal-title":"Lancet Infect. Dis."},{"issue":"10240","key":"10.1016\/j.biopha.2021.112282_bib176","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.biopha.2021.112282_bib177","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1517\/14712598.2.8.895","article-title":"Reverse vaccinology: a genome-based approach for vaccine development","volume":"2","author":"Masignani","year":"2002","journal-title":"Expert Opin. Biol. Ther."},{"issue":"7","key":"10.1016\/j.biopha.2021.112282_bib178","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/qjmed\/93.7.391","article-title":"Impact of genomics on drug discovery and clinical medicine","volume":"93","author":"Emilien","year":"2000","journal-title":"Qjm"},{"issue":"R2","key":"10.1016\/j.biopha.2021.112282_bib179","doi-asserted-by":"crossref","first-page":"R166","DOI":"10.1093\/hmg\/ddw246","article-title":"Precision medicine, genomics and drug discovery","volume":"25","author":"Cardon","year":"2016","journal-title":"Hum. Mol. Genet."},{"issue":"7","key":"10.1016\/j.biopha.2021.112282_bib180","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2174\/0929866526666190311163820","article-title":"Bispecific antibody (bsAb) construct formats and their application in cancer therapy","volume":"26","author":"Acheampong","year":"2019","journal-title":"Protein Pept. Lett."},{"issue":"3","key":"10.1016\/j.biopha.2021.112282_bib181","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/CJI.0000000000000157","article-title":"A novel fusion antibody exhibits antiangiogenic activity and stimulates NK cell-mediated immune surveillance through fused NKG2D ligand","volume":"40","author":"Acheampong","year":"2017","journal-title":"J. Immunother."},{"issue":"2","key":"10.1016\/j.biopha.2021.112282_bib182","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/btpr.2231","article-title":"A novel bispecific diabody targeting both vascular endothelial growth factor receptor 2 and epidermal growth factor receptor for enhanced antitumor activity","volume":"32","author":"Xu","year":"2016","journal-title":"Biotechnol. Prog."},{"issue":"2","key":"10.1016\/j.biopha.2021.112282_bib183","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/15384047.2015.1121344","article-title":"A human IgG-like bispecific antibody co-targeting epidermal growth factor receptor and the vascular endothelial growth factor receptor 2 for enhanced antitumor activity","volume":"17","author":"Chen","year":"2016","journal-title":"Cancer Biol. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2021.112282_bib184","doi-asserted-by":"crossref","first-page":"456","DOI":"10.2174\/0929866524666170120095128","article-title":"Bispecific antibodies (bsAbs): promising immunotherapeutic agents for cancer therapy","volume":"24","author":"Acheampong","year":"2017","journal-title":"Protein Pept. Lett."},{"key":"10.1016\/j.biopha.2021.112282_bib185","article-title":"Prospect of reprogramming replication licensing for cancer drug development","volume":"136","author":"Barffour","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"7","key":"10.1016\/j.biopha.2021.112282_bib186","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1073\/pnas.97.7.3515","article-title":"Vaccination with tat toxoid attenuates disease in simian\/HIV-challenged macaques","volume":"97","author":"Pauza","year":"2000","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2021.112282_bib187","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/9488","article-title":"Control of SHIV-89.6 P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine","volume":"5","author":"Cafaro","year":"1999","journal-title":"Nat. Med."},{"issue":"20\u201321","key":"10.1016\/j.biopha.2021.112282_bib188","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1016\/S0264-410X(98)00498-8","article-title":"Vaccination with Rev and Tat against AIDS","volume":"17","author":"Osterhaus","year":"1999","journal-title":"Vaccine"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221010660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221010660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:28:20Z","timestamp":1760099300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221010660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":188,"alternative-id":["S0753332221010660"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112282","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112282","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112282"}}